ProCE Banner Activity

LAURA: Updated Overall Survival for Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy for Unresectable Stage III EGFR-Mutated NSCLC

Conference Coverage
Slideset

Updated results from the phase III LAURA trial showed improved postprogression outcomes and a continuing trend in overall survival benefit for osimertinib vs placebo for patients with unresectable stage III EGFR-mutated NSCLC without progression during or after chemoradiotherapy.

Released: April 09, 2025

Expiration: October 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc